1
|
Thomas DG, Erpenbach H, Hickey RW, Waltzman D, Haarbauer-Krupa J, Nelson LD, Patterson CG, McCrea MA, Collins MW, Kontos AP. Implementation of active injury management (AIM) in youth with acute concussion: A randomized controlled trial. Contemp Clin Trials 2022; 123:106965. [PMID: 36252936 PMCID: PMC10924688 DOI: 10.1016/j.cct.2022.106965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Revised: 09/10/2022] [Accepted: 10/11/2022] [Indexed: 01/27/2023]
Abstract
BACKGROUND Nearly 2 million youth seek acute medical care following concussion in the U.S. each year. Current standard of care recommends rest for the first 48 h after a concussion. However, research suggests that prolonged rest may lengthen recovery time especially for patients with certain risk profiles. Research indicates that physical activity and behavioral management interventions (sleep, stress management) may enhance recovery. To date, there is limited empirical evidence to inform acute (<72 h) concussion recommendations for physical activity and behavioral management in adolescents. OBJECTIVE To determine the effectiveness of physical activity and behavioral management for acute concussion in adolescents and young adults, and to evaluate the role of patient characteristics on treatment response. METHODS This multicenter prospective randomized controlled trial will determine which combination of physical activity and behavioral management is most effective for patients 11-24 years old who present to the emergency department or concussion clinic within 72 h of injury. Participants are randomized into: 1) rest, 2) physical activity, 3) mobile health application (mHealth) behavioral management, or 4) physical activity and mHealth app conditions. Assessments at enrollment, 3-5 days, 14 days, 1 month, and 2 months include: concussion symptoms, balance, vestibular-ocular and cognitive assessments, quality of life, and recovery time. Somatic symptoms and other risk factors are evaluated at enrollment. Compliance with treatment and symptoms are assessed daily using actigraph and daily self-report. The primary study outcome is symptoms at 14 days. CONCLUSION Prescribed physical activity and behavioral management may improve outcomes in youth following acute concussion.
Collapse
Affiliation(s)
- D G Thomas
- Medical College of Wisconsin, Department of Pediatrics, United States of America.
| | - H Erpenbach
- Medical College of Wisconsin, Department of Pediatrics, United States of America
| | - R W Hickey
- University of Pittsburgh, Department of Pediatrics, United States of America
| | - D Waltzman
- Centers for Disease Control and Prevention, United States of America
| | - J Haarbauer-Krupa
- Centers for Disease Control and Prevention, United States of America
| | - L D Nelson
- Medical College of Wisconsin, Department of Neurosurgery, United States of America
| | - C G Patterson
- University of Pittsburgh, Department of Physical Therapy, United States of America
| | - M A McCrea
- Medical College of Wisconsin, Department of Neurosurgery, United States of America
| | - M W Collins
- University of Pittsburgh, Department of Orthopedic Surgery, United States of America
| | - A P Kontos
- University of Pittsburgh, Department of Orthopedic Surgery, United States of America
| |
Collapse
|
2
|
Abstract
The aim of this review is to summarise the available literature on the effects of consuming raw, red meat diets on the gastrointestinal microbiome of the cat and dog. In recent years, feeding raw meat diets to cats and dogs has increased, in part associated with trends in human nutrition for "natural" and "species-appropriate" diets. These diets range from home-prepared unprocessed, nutritionally incomplete diets to complete and balanced diets with sterilisation steps in their manufacturing process. Feeding some formats of raw meat diets has been associated with nutritional inadequacies and zoonotic transfer of pathogens. The feeding of raw meat diets has been shown to alter the gastrointestinal microbiome of the cat and dog, increasing the relative abundances of bacteria associated with protein and fat utilisation, including members of the genera Fusobacterium and Clostridium. While in humans, these genera are more commonly known for members that are associated with disease, they are a diverse group that also contains harmless commensals that are a normal component of the gastrointestinal microbiota. Moreover, members of these genera are known to produce butyrate from protein and amino acid fermentation and contribute to intestinal homeostasis in raw meat-fed dogs and cats. Currently, only a limited number of studies have examined the impacts of raw meat diets on the cat and dog microbiota, with many of these being descriptive. Additional controlled and systems-based studies are required to functionally characterise the roles of key microbial groups in the metabolism of raw meat diets, and determine their impacts on the health and nutrition of the host.
Collapse
Affiliation(s)
- C F Butowski
- Smart Foods, AgResearch Limited, Palmerston North, New Zealand
| | - C D Moon
- Resilient Agriculture, AgResearch Limited, Grasslands Research Centre, Palmerston North, New Zealand
| | - D G Thomas
- Centre for Feline Nutrition, Massey University, Palmerston North, New Zealand
| | - W Young
- Smart Foods, AgResearch Limited, Palmerston North, New Zealand
| | - E N Bermingham
- Smart Foods, AgResearch Limited, Palmerston North, New Zealand
| |
Collapse
|
3
|
Wood RM, Pratt AC, Murch BJ, Powell AL, Booton RD, Thomas DG, Twigger J, Diakou E, Coleborn S, Manning T, Davies C, Turner KM. Establishing an SEIR-based framework for local modelling of COVID-19 infections, hospitalisations and deaths. Health Syst (Basingstoke) 2021; 10:337-347. [PMID: 34745593 PMCID: PMC8567954 DOI: 10.1080/20476965.2021.1973348] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Accepted: 08/19/2021] [Indexed: 12/13/2022] Open
Abstract
Without timely assessments of the number of COVID-19 cases requiring hospitalisation, healthcare providers will struggle to ensure an appropriate number of beds are made available. Too few could cause excess deaths while too many could result in additional waits for elective treatment. As well as supporting capacity considerations, reliably projecting future "waves" is important to inform the nature, timing and magnitude of any localised restrictions to reduce transmission. In making the case for locally owned and locally configurable models, this paper details the approach taken by one major healthcare system in founding a multi-disciplinary "Scenario Review Working Group", comprising commissioners, public health officials and academic epidemiologists. The role of this group, which met weekly during the pandemic, was to define and maintain an evolving library of plausible scenarios to underpin projections obtained through an SEIR-based compartmental model. Outputs have informed decision-making at the system's major incident Bronze, Silver and Gold Commands. This paper presents illustrated examples of use and offers practical considerations for other healthcare systems that may benefit from such a framework.
Collapse
Affiliation(s)
- R. M. Wood
- Bristol, North Somerset and South Gloucestershire CCG, National Health Service, Bristol, UK
- School of Management, University of Bath, Bath, UK
| | - A. C. Pratt
- Bristol, North Somerset and South Gloucestershire CCG, National Health Service, Bristol, UK
| | - B. J. Murch
- Bristol, North Somerset and South Gloucestershire CCG, National Health Service, Bristol, UK
| | - A. L. Powell
- Bristol, North Somerset and South Gloucestershire CCG, National Health Service, Bristol, UK
| | - R. D. Booton
- Bristol Medical School, University of Bristol, Bristol, UK
| | - D. G. Thomas
- Public Health, Bristol City Council, Bristol, UK
| | - J. Twigger
- Public Health, Bristol City Council, Bristol, UK
| | - E. Diakou
- Business Intelligence, North Somerset Council, Weston-Super-Mare, UK
| | - S. Coleborn
- Public Health, South Gloucestershire Council, Yate, UK
| | - T. Manning
- Bristol, North Somerset and South Gloucestershire CCG, National Health Service, Bristol, UK
| | - C. Davies
- Bristol, North Somerset and South Gloucestershire CCG, National Health Service, Bristol, UK
| | - K. M. Turner
- Bristol Medical School, University of Bristol, Bristol, UK
| |
Collapse
|
4
|
Chugh R, Griffith KA, Davis EJ, Thomas DG, Zavala JD, Metko G, Brockstein B, Undevia SD, Stadler WM, Schuetze SM. Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol 2019; 30:1405. [PMID: 30726873 PMCID: PMC7360153 DOI: 10.1093/annonc/mdy557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
5
|
Anderson RC, Armstrong KM, Young W, Maclean P, Thomas DG, Bermingham EN. Effect of kibble and raw meat diets on peripheral blood mononuclear cell gene expression profile in dogs. Vet J 2018; 234:7-10. [PMID: 29680397 DOI: 10.1016/j.tvjl.2018.01.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2017] [Revised: 01/22/2018] [Accepted: 01/24/2018] [Indexed: 02/03/2023]
Abstract
Peripheral blood mononuclear cell (PBMC) gene expression microarray profiling is a minimally invasive tool used in human diet intervention studies. In this study, PBMC gene expression was determined in dogs fed kibble or raw red meat diets for 9 weeks to test the hypothesis that diet influences canine immune cell gene expression profiles. The two diets were associated with differences in PBMC gene expression profiles, which corresponded with changes in plasma IgA concentrations. Analysis of PBMC gene expression profiles might provide useful insights into the long term effects of diet on health outcomes in dogs.
Collapse
Affiliation(s)
- R C Anderson
- Food Nutrition and Health Team, AgResearch, Palmerston North, New Zealand; Riddet Institute, Massey University, Palmerston North, New Zealand
| | - K M Armstrong
- Food Nutrition and Health Team, AgResearch, Palmerston North, New Zealand
| | - W Young
- Food Nutrition and Health Team, AgResearch, Palmerston North, New Zealand; Riddet Institute, Massey University, Palmerston North, New Zealand
| | - P Maclean
- Bioinformatics and Statistics Team, AgResearch, Lincoln, New Zealand
| | - D G Thomas
- Institute of Veterinary, Animal and Biomedical Sciences, Massey University, Palmerston North, New Zealand
| | - E N Bermingham
- Food Nutrition and Health Team, AgResearch, Palmerston North, New Zealand.
| |
Collapse
|
6
|
White JD, Cave NJ, Grinberg A, Thomas DG, Heuer C. Subclinical Bacteriuria in Older Cats and its Association with Survival. J Vet Intern Med 2018; 30:1824-1829. [PMID: 27859751 PMCID: PMC5115191 DOI: 10.1111/jvim.14598] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2015] [Revised: 07/29/2016] [Accepted: 09/19/2016] [Indexed: 12/01/2022] Open
Abstract
Background Bacterial urinary tract infections are uncommon in cats in general but the prevalence increases to 29% in older cats with comorbidities (Veterinary Clinical Pathology 2008, 37, 317; Journal of Feline Medicine & Surgery 2007, 9, 124; Veterinary Microbiology 2009, 136, 130). Frequently, the infections are subclinical. The clinical relevance of subclinical bacteriuria (SB) is uncertain, and the optimal treatment requires clarification. Objective Prospective, observational study to: (i) identify the prevalence and incidence count of SB in older (≥7 years), nonazotemic cats, (ii) evaluate specific risk factors for SB, and (iii) investigate the potential relationship between untreated SB and survival. Animals Sixty‐seven, nonazotemic cats were tested on 5 occasions over 3 years. Methods Urine samples were obtained by cystocentesis for quantitative urine culture and blood samples for measurement of serum creatinine concentration. Episodes of SB were not treated. Serum creatinine concentration, body weight, urine specific gravity, sex, and age were evaluated as potential risk factors for a positive urine culture. The association between urine culture results and survival was evaluated with Cox's proportional hazard model. Results A total of 256 urine samples was obtained. The prevalence of SB varied between 10 and 13%, and incident infections were uncommon. Female cats were 21 times more likely to have a positive urine culture than were male cats (odds ratio [OR], 21.2; confidence interval [CI], 4.1–110; P = .00028). Subclinical bacteriuria was not significantly associated with survival. Conclusion and clinical importance Subclinical bacteriuria is common in nonazotemic, older cats. Although antimicrobial treatment was withheld, the presence of SB was not adversely associated with survival.
Collapse
Affiliation(s)
- J D White
- Massey University Veterinary Teaching Hospital, Palmerston North, New Zealand
| | - N J Cave
- Institute of Veterinary, Animal & Biomedical Sciences, Palmerston North, New Zealand
| | - A Grinberg
- Institute of Veterinary, Animal & Biomedical Sciences, Palmerston North, New Zealand
| | - D G Thomas
- Institute of Veterinary, Animal & Biomedical Sciences, Palmerston North, New Zealand
| | - C Heuer
- EpiCentre, Massey University, Palmerston North, New Zealand
| |
Collapse
|
7
|
Roberts MT, Bermingham EN, Cave NJ, Young W, McKenzie CM, Thomas DG. Macronutrient intake of dogs, self-selecting diets varying in composition offered ad libitum. J Anim Physiol Anim Nutr (Berl) 2017; 102:568-575. [PMID: 29024089 DOI: 10.1111/jpn.12794] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2016] [Accepted: 07/11/2017] [Indexed: 11/28/2022]
Abstract
The diet of the domestic dog has changed significantly from that of its wolf ancestor, with to date only two studies having examined macronutrient self-selection in dogs. Whilst the first focused solely on protein intake, determining an intake of 30% metabolisable energy (ME), the second investigated dietary protein, fat and carbohydrate (PFC), indicating an intake ratio of 30:63:7% by energy. This study's aim was to further elucidate macronutrient intake by providing greater macronutrient range, energy content, and to investigate over a longer duration than previous studies. Fifteen adult dogs were given access to three wet diets providing 500% of daily ME, twice daily over 10 days. The diets were nutritionally complete and formulated using the same four ingredients in different proportions to supply high levels of protein (58% ME), fat (86% ME) or carbohydrate (54% ME). Overall fat and carbohydrate consumption significantly declined from 6,382 to 917 kcals per day (p < 0.001) and 553 to 214 kcals day-1 (p < .01) respectively. Protein intake, however, remained constant over the study and ranged from 4,786 to 4,156 kcals day-1 . Such results impacted on percentage total energy intake, with fat decreasing from 68% to 52% (p < .001) and protein increasing from 29% to 44% (p < .01). Our findings suggest that dogs still possess a "feast or famine" mentality, wherein energy dense fat is prioritised over protein initially. With continued feeding over 10 days, a transition to a more balanced energy contribution from both macronutrients is evident. The study also shows that given the option, dogs do not select carbohydrate to be a significant portion of the diet. The health implications of such dietary selection are of interest.
Collapse
Affiliation(s)
- M T Roberts
- Food Nutrition & Health Team, Food & Bio-based Products, AgResearch Grasslands, Palmerston North, New Zealand.,Institute of Veterinary Animal Biomedical Sciences, Massey University, Palmerston North, New Zealand
| | - E N Bermingham
- Food Nutrition & Health Team, Food & Bio-based Products, AgResearch Grasslands, Palmerston North, New Zealand
| | - N J Cave
- Institute of Veterinary Animal Biomedical Sciences, Massey University, Palmerston North, New Zealand
| | - W Young
- Food Nutrition & Health Team, Food & Bio-based Products, AgResearch Grasslands, Palmerston North, New Zealand
| | - C M McKenzie
- Bioinformatics & Statistics Team, AgResearch Grasslands, Palmerston North, New Zealand
| | - D G Thomas
- Institute of Veterinary Animal Biomedical Sciences, Massey University, Palmerston North, New Zealand
| |
Collapse
|
8
|
Affiliation(s)
- D. G. Thomas
- Indiana University and Birkbeck College, University of London
| | - James B. Appel
- Indiana University and Birkbeck College, University of London
| | | |
Collapse
|
9
|
Thamm DH, Hayes DF, Meuten T, Laver T, Thomas DG. Epithelial Cell Adhesion Molecule Expression in Canine Tumours. J Comp Pathol 2016; 155:299-304. [PMID: 27567927 DOI: 10.1016/j.jcpa.2016.07.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2016] [Revised: 06/09/2016] [Accepted: 07/21/2016] [Indexed: 01/12/2023]
Abstract
Epithelial cell adhesion molecule (EpCAM) is expressed in most human normal and neoplastic tissues of epithelial derivation and may have an association with tumour cell aggressiveness, a stem cell-like phenotype and clinical outcome. Antibody-based strategies for the targeting and capture of EpCAM-expressing tumour cells are showing promise, both as diagnostic tools and potential therapies. The aim of this study was to assess EpCAM expression in canine tumours. EpCAM expression was assessed in tumour cell lines via gene expression profiling and in formalin-fixed and paraffin wax-embedded tissues from canine carcinomas representing various anatomical sites by immunohistochemistry. EpCAM mRNA expression was higher in cell lines from carcinomas than those derived from sarcomas or haemopoietic tumours. EpCAM was expressed by >2/3 of tumour cells in 71% of canine carcinomas evaluated, irrespective of histotype, with the exception of carcinomas of the adrenal gland. Canine sarcomas and haemopoietic tumours were uniformly negative. Most canine carcinomas express EpCAM and so could be suitable for the study of EpCAM-directed diagnostics and therapeutics.
Collapse
Affiliation(s)
- D H Thamm
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA; Cell and Molecular Biology Graduate Program, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA; University of Colorado Comprehensive Cancer Center, 1665 N. Ursula St., Aurora, CO, USA.
| | - D F Hayes
- Comprehensive Cancer Center, University of Michigan, 1500 E. Medical Center Drive SPC 5942, Ann Arbor, MI, USA
| | - T Meuten
- Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA
| | - T Laver
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA
| | - D G Thomas
- Comprehensive Cancer Center, University of Michigan, 1500 E. Medical Center Drive SPC 5942, Ann Arbor, MI, USA
| |
Collapse
|
10
|
Hawkes CH, Cavanagh JB, Darling JL, Watkins BA, Thomas DG. Chronic Low-Dose Exposure of Sodium Nitrite in VM-Strain Mice: Central Nervous System Changes. Hum Exp Toxicol 2016; 11:279-81. [PMID: 1354977 DOI: 10.1177/096032719201100408] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
1 There is suggestive evidence that nitrite may be a causative factor in cerebral glioma. 2 To test this hypothesis we selected the VM mouse strain, known for its susceptibility to spontaneous glioma formation, and exposed 300 animals to 0.2% sodium nitrite in their drinking water. One hundred of this group were exposed both in utero and throughout their adult lives. The remaining 200 animals received nitrite from the time of weaning. A further 200 mice were used as controls and received distilled water. 3 All animals were maintained until their natural death and were then subjected to autopsy and routine histological examination. 4 There was no excess of nervous system tumours in the experimental groups.
Collapse
Affiliation(s)
- C H Hawkes
- Gough-Cooper Department of Neurological Surgery, Institute of Neurology, London, UK
| | | | | | | | | |
Collapse
|
11
|
Paoletti C, Cani AK, Aung K, Darga EP, Cannell EM, Hovelson DH, Yazdani M, Blevins AR, Tokudome N, Larios JM, Thomas DG, Brown ME, Gersch C, Schott AF, Robinson DR, Chinnaiyan AM, Bischoff F, Hayes DF, Rae JM, Tomlins SA. Abstract P2-02-19: Somatic genetic profiling of circulating tumor cells (CTC) in metastatic breast cancer (MBC) patients. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-02-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Somatic mutations, including those in TP53, PIK3CA, and estrogen receptor alpha (ESR1), are key to the biology of cancer and response to therapy. Recently, somatic cancer-associated mutations have been identified in circulating cell free plasma tumor DNA (ptDNA). Less is known about the mutation profile of DNA extracted from CTC (CTC-DNA). Since CTC-DNA provides mutational information of single cells, we hypothesize CTC-DNA will complement ptDNA to give greater insight into tumor heterogeneity.
Methods: Patients with ER positive MBC who were enrolled in the Mi CTC-ONCOSEQ, a companion trial to Mi-ONCOSEQ (the Michigan Oncology Sequencing Program), and who had ≥5CTC/7.5 ml whole blood were included. CTC were enriched from white blood cells (WBC) with CellSearch© (CXC kit). CTC and WBC were then purified using DEPArrayTM. DNA from individual CTC and WBC was isolated and subjected to whole genomic amplification (Ampli 1TM WGA). Genetic analysis was performed on individual CTC, pooled CTC and pooled WBC DNA by multiplexed PCR based targeted next generation sequencing (NGS) using the Oncomine Comprehensive Panel (targeting ∼130 onco- and tumor suppressor genes) and the Ion Torrent Proton. All patients had exome sequencing performed on research biopsies of metastases using an Illumina HiSeq 2500 platform.
Results: This pilot study was conducted using high quality DNA from two patients assessed to date. Both patients had lobular carcinoma and as expected harbored somatic, deleterious CDH1 (E-cadherin) mutations (frameshift and non-sense) in both research biopsy and CTC-DNA. These data supported our approach. Patient #1 was TP53 wild type in her research biopsy, but multiple CTC harbored somatic TP53 frame-shift mutations (Table). Patient #2 harbored an ESR1 Y537S mutation in her research biopsy. However, only 4 of 7 CTC also harbored this somatic, heterozygous mutation.
Prioritized mutations in CTCPt#Cell Type (CTC vs WBC), numberGeneMutationVariant fraction (expected 1=homozygous; 0.5=heterozygous)Found in research biopsy?1CTC_A2CDH1p.I584fs1YES CTC_A4 1 CTC_A7 0.54 CTC_pool* 0.74 WBC_pool 0 CTC_A2TP53p.152_156del1NO CTC_A4 1 CTC_A7 0.51 CTC_pool* 0.88 WBC_pool 0 2CTC_A9ESR1p.Y537S0.52YES CTC_D1 0.34 CTC_D2 0.46 CTC_D6 0.65 CTC_pool* 0.35 WBC_pool 0 CTC_A12 0 CTC_D3 0 CTC_D7 0 CTC_A12CDH1p.Q641X1YES CTC_A9 1 CTC_D1 1 CTC_D3 1 CTC_D6 1 CTC_pool* 1 WBC_pool 0 * pool of all CTC
Conclusions: We demonstrate the ability to purify CTC, isolate, and amplify DNA of suitable quality for genetic analysis using a comprehensive targeted sequencing panel. Both known and novel alterations were identified in comparison to research biopsy specimens. This approach allows single cell analysis demonstrating heterogeneity of mutational status in different single cells. Studies of CTC-ESR1 and other genetic abnormalities in patients with known tissue mutations who participated in Mi CTC-ONCOSEQ are now underway.
Citation Format: Paoletti C, Cani AK, Aung K, Darga EP, Cannell EM, Hovelson DH, Yazdani M, Blevins AR, Tokudome N, Larios JM, Thomas DG, Brown ME, Gersch C, Schott AF, Robinson DR, Chinnaiyan AM, Bischoff F, Hayes DF, Rae JM, Tomlins SA. Somatic genetic profiling of circulating tumor cells (CTC) in metastatic breast cancer (MBC) patients. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-02-19.
Collapse
Affiliation(s)
- C Paoletti
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - AK Cani
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - K Aung
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - EP Darga
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - EM Cannell
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - DH Hovelson
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - M Yazdani
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - AR Blevins
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - N Tokudome
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - JM Larios
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - DG Thomas
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - ME Brown
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - C Gersch
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - AF Schott
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - DR Robinson
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - AM Chinnaiyan
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - F Bischoff
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - DF Hayes
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - JM Rae
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| | - SA Tomlins
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; Silicon Biosystems, Inc., San Diego, CA
| |
Collapse
|
12
|
Paoletti C, Aung K, Cannell EM, Darga EP, Chu D, Kidwell KM, Thomas DG, Tokudome N, Brown ME, McNutt LM, Gersch C, Schott AF, Park BH, Robinson DR, Chinnaiyan AM, Rae JM, Hayes DF. Abstract P3-05-01: Molecular analysis of cancer tissue, circulating tumor cells (CTC) and cell-free plasma tumor DNA (ptDNA) suggests variable mechanisms of resistance to endocrine therapy (ET) in estrogen receptor (ER) positive metastatic breast cancer (MBC). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-05-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Fifty percent of ER positive MBC patients do not benefit from ET. Potential mechanisms of resistance to ET in this patient population include absence of ER expression by deletion or suppression, alteration in ER signaling pathway genes, or upregulation of multiple growth factor receptor pathways. We hypothesized that genotyping and phenotyping of CTC combined with genomic analysis of ptDNA will provide important insights into the multiple mechanisms of ET resistance and that a set of blood tests might serve as a "liquid biopsy" abrogating the need for tissue specimens.
Methods: Twenty-four patients providing informed consent were enrolled into the Mi CTC-ONCOSEQ study, a companion trial to Mi-ONCOSEQ (the Michigan Oncology Sequencing Program). Seven of these patients (5 with ER immunohistochemistry (IHC) positive and 2 with ER negative cancers) who had available archived primary and metastatic cancer tissue, a research metastatic biopsy for genomic analysis, and who had ≥5CTC/7.5 ml whole blood (WB) characterized for ER protein (CTC-ER) are the focus of this report. All the patients were ET refractory. None of them was progressing on fulvestrant at the time of study entry. CTC enumeration and phenotyping was performed with CellSearch©. Circulating ptDNA was analyzed by droplet digital polymerase chain reaction (ddPCR). ER status from archived tissue was obtained from chart review. ER mRNA expression was determined in the research biopsy of metastatic tissue by using quantitative RNA sequencing. Mutational status of ER gene, ESR1, was determined by Next-gen Sequencing using the Illumina HiSeq 2500 platform.
Results: The 2 control patients with triple negative breast cancer had negative CTC-ER. Discordance between CTC-ER and tissue ER by IHC was observed (Table). Two of the 5 ER positive patients retained CTC-ER positivity (39% and 19% of the CTC). One of them (#7) harbored an ESR1 mutation in the research biopsy tissue and in ptDNA, whereas the other (#14) had wild type (WT) ESR1. CTC-ER protein levels in patients #12, 17 and 24 were negative. All had WT ESR1 in the research biopsy tissue. Of note, patient #12 had WT ESR1 in the research biopsy, but an ESR1 mutation was detected in her ptDNA.
Pt#CTC-ER Tissue-ER ESR1 status in research biopsyESR1 status in ptDNA N[deg]CTC/7.5ml WB% CTC-ER +Primary by IHCMet by IHCMet research biopsy by mRNA 71839%+++Y537SY537S141619%+NA+WTWT12130%+++WTD538G17160%++weakly+WTWT242750%+weakly+weakly+WTWT
Conclusions: These exploratory data suggest heterogeneous mechanisms of resistance to ET in patients with previously determined ER-positive MBC, including ESR1 mutations in ER positive cases (seen in 2 patients) and loss of ER expression (seen in CTC of 3 patients). In contrast, other cancers continue to express WT ESR1, and therefore must have developed alternative mechanisms of resistance. At least 2 of these mechanisms can be detected and monitored with complementary circulating assays: CTC and ptDNA. Further investigations are needed to understand the heterogeneous mechanisms of resistance to ET.
Citation Format: Paoletti C, Aung K, Cannell EM, Darga EP, Chu D, Kidwell KM, Thomas DG, Tokudome N, Brown ME, McNutt LM, Gersch C, Schott AF, Park BH, Robinson DR, Chinnaiyan AM, Rae JM, Hayes DF. Molecular analysis of cancer tissue, circulating tumor cells (CTC) and cell-free plasma tumor DNA (ptDNA) suggests variable mechanisms of resistance to endocrine therapy (ET) in estrogen receptor (ER) positive metastatic breast cancer (MBC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-05-01.
Collapse
Affiliation(s)
- C Paoletti
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - K Aung
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - EM Cannell
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - EP Darga
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - D Chu
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - KM Kidwell
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - DG Thomas
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - N Tokudome
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - ME Brown
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - LM McNutt
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - C Gersch
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - AF Schott
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - BH Park
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - DR Robinson
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - AM Chinnaiyan
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - JM Rae
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - DF Hayes
- University of Michigan Comprehensive Cancer Center (UM CCC), Ann Arbor, MI; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| |
Collapse
|
13
|
|
14
|
|
15
|
Chugh R, Griffith KA, Davis EJ, Thomas DG, Zavala JD, Metko G, Brockstein B, Undevia SD, Stadler WM, Schuetze SM. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol 2015; 26:1459-64. [PMID: 25858498 DOI: 10.1093/annonc/mdv171] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2014] [Accepted: 03/27/2015] [Indexed: 01/02/2023] Open
Abstract
BACKGROUND Insulin-like growth factor receptor (IGF-1R) has been studied as an oncologic target in soft tissue sarcoma (STS), but its role in sarcoma biology is unclear. Anti-IGF-1R antibody cixutumumab demonstrated acceptable toxicity but limited activity as a single agent in STS. We carried out a dose-escalation study of cixutumumab with doxorubicin to evaluate safety and dosing of the combination. PATIENTS AND METHODS Eligible patients with advanced STS were treated with cixutumumab intravenously on days 1/8/15 at one of three dose levels (A: 1 mg/kg, B: 3 mg/kg, C: 6 mg/kg) with doxorubicin at 75 mg/m(2) as a 48 h infusion on day 1 of a 21 day cycle. After six cycles of the combination, patients could receive cixutumumab alone. The Time-to-Event Continual Reassessment Method was used to estimate the probability of dose-limiting toxicity (DLT) and to assign patients to the dose with an estimated probability of DLT≤20%. RESULTS Between September 2008 and January 2012, 30 patients with advanced STS received a median of six cycles of therapy (range <1-22). Two DLTs were observed, grade 3 mucositis (dose level B) and grade 4 hyperglycemia (dose level C). Grade 2 and 3 reduced left ventricular ejection fraction was seen in three and two patients, respectively. Five partial responses were observed, and estimated progression-free survival was 5.3 months (95% confidence interval 3.0-6.3) in 26 response-assessable patients. Immunohistochemical staining of 11 available tumor samples for IGF-1R and phospho-IGF-1R was not significantly different among responders and non-responders, and serum analysis of select single-nucleotide polymorphisms did not predict for cardiotoxicity. CONCLUSION The maximum tolerated dose was doxorubicin 75 mg/m(2) on day 1 and cixitumumab 6 mg/kg on days 1/8/15 of a 21 day cycle. Cardiac toxicity was observed and should be monitored in subsequent studies, which should be considered in STS only if a predictive biomarker of benefit to anti-IGF-1R therapy is identified. TRIAL REGISTRATION ClinicalTrials.gov:NCT00720174.
Collapse
Affiliation(s)
- R Chugh
- Departments of Internal Medicine, University of Michigan, Ann Arbor
| | - K A Griffith
- Biostatistics, University of Michigan, Ann Arbor
| | - E J Davis
- Departments of Internal Medicine, University of Michigan, Ann Arbor
| | - D G Thomas
- Pathology, University of Michigan, Ann Arbor
| | - J D Zavala
- Cancer Clinical Trials Office, University of Chicago, Chicago
| | - G Metko
- Clinical Trials Office, University of Michigan, Ann Arbor
| | | | - S D Undevia
- Department of Medicine, University of Chicago, Chicago, USA
| | - W M Stadler
- Department of Medicine, University of Chicago, Chicago, USA
| | - S M Schuetze
- Departments of Internal Medicine, University of Michigan, Ann Arbor
| |
Collapse
|
16
|
Dijcker JC, Hagen-Plantinga EA, Thomas DG, Queau Y, Biourge V, Hendriks WH. The effect of dietary hydroxyproline and dietary oxalate on urinary oxalate excretion in cats. J Anim Sci 2014; 92:577-84. [PMID: 24664562 DOI: 10.2527/jas.2013-6178] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
In humans and rodents, dietary hydroxyproline (hyp) and oxalate intake affect urinary oxalate (Uox) excretion. Whether Uox excretion occurs in cats was tested by feeding diets containing low oxalate (13 mg/100 g DM) with high (Hhyp-Lox), moderate (Mhyp-Lox), and low hyp (Lhyp-Lox) concentrations (3.8, 2.0, and 0.2 g/100 g DM, respectively) and low hyp with high oxalate (93 mg/100 g DM; Lhyp-Hox) to 8 adult female cats in a 48-d study using a Latin square design. Cats were randomly allocated to one of the four 12-d treatment periods and fed according to individual energy needs. Feces and urine were collected quantitatively using modified litter boxes during the final 5 d of each period. Feces were analyzed for oxalate and Ca, and urine was analyzed for specific density, pH, oxalate, Ca, P, Mg, Na, K, ammonia, citrate, urate, sulfate, and creatinine. Increasing hyp intake (0.2, 2.0, and 3.8 g/100 g DM) resulted in increased Uox excretion (Lhyp-Lox vs. Mhyp-Lox vs. Hhyp-Lox; P < 0.05), and the linear dose-response equation was Uox (mg/d) = 5.62 + 2.10 × g hyp intake/d (r(2) = 0.56; P < 0.001). Increasing oxalate intake from 13 to 93 mg/100 g DM did not affect Uox excretion but resulted in an increase in fecal oxalate output (P < 0.001) and positive oxalate balance (32.20 ± 2.06 mg/d). The results indicate that the intestinal absorption of the supplemental oxalate, and thereby its contribution to Uox, was low (5.90% ± 5.24%). Relevant increases in endogenous Uox excretion were achieved by increasing dietary hyp intake. The hyp-containing protein sources should be minimized in Ca oxalate urolith preventative diets until their effect on Uox excretion is tested. The oxalate content (up to 93 mg/100 g DM) in a diet with moderate Ca content does not contribute to Uox content.
Collapse
Affiliation(s)
- J C Dijcker
- Faculty of Veterinary Medicine, Utrecht University, 3584 CL Utrecht, The Netherlands
| | | | | | | | | | | |
Collapse
|
17
|
Kim G, Ouzounova M, Quraishi AA, Davis A, Tawakkol N, Clouthier SG, Malik F, Paulson AK, D'Angelo RC, Korkaya S, Baker TL, Esen ES, Prat A, Liu S, Kleer CG, Thomas DG, Wicha MS, Korkaya H. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. Oncogene 2014; 34:671-80. [PMID: 24531711 PMCID: PMC4285772 DOI: 10.1038/onc.2014.4] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2013] [Revised: 12/18/2013] [Accepted: 01/06/2014] [Indexed: 02/07/2023]
Abstract
Somatic mutations or deletions of TP53 and PTEN in ductal carcinoma in situ (DCIS) lesions have been implicated in progression to invasive ductal carcinomas. A recent molecular and mutational analysis of breast cancers revealed that inactivation of tumor suppressors, p53 and PTEN are strongly associated with triple negative breast cancer. In addition, these tumor suppressors play important roles in regulating self-renewal in normal and malignant stem cells. To investigate their role in breast carcinogenesis, we knocked down these genes in human mammary cells and in non-transformed MCF10A cells. p53 and PTEN knockdown synergized to activate pro-inflammatory IL6/Stat3/NF-κB signaling. This resulted in generation of highly metastatic EMT-like cancer stem cells (CSCs) resulting in tumors whose gene expression profile mimicked that found in basal/claudin-low molecular subtype within the triple negative breast tumors. Constitutive activation of this loop in transformed cells was dependent on proteolytic degradation of SOCS3 resulting in low levels of this protein in basal/claudin low cell lines and primary tumors. In non-transformed cells, transient activation of the IL6 inflammatory loop induced SOCS3 expression leading to pathway inactivation. In transformed cells, enforced expression of SOCS3 or interfering with IL6 pathway via IL6R blockade inhibited tumor growth and metastasis in mouse xenograft models. Furthermore, circulating tumor cells were significantly reduced in tumor bearing animals when treated with anti-IL6R antibodies. These studies uncover important connections between inflammation and carcinogenesis and suggest that blocking pro-inflammatory cytokines may be utilized as an attractive strategy to target triple negative breast tumors which currently lacks molecularly targeted therapies.
Collapse
Affiliation(s)
- G Kim
- 1] Comprehensive Cancer Center, Department of Internal medicine, University of Michigan, Ann Arbor, MI, USA [2] Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam 463-712, Gyeonggi, Republic of Korea
| | - M Ouzounova
- Comprehensive Cancer Center, Department of Internal medicine, University of Michigan, Ann Arbor, MI, USA
| | - A A Quraishi
- Comprehensive Cancer Center, Department of Internal medicine, University of Michigan, Ann Arbor, MI, USA
| | - A Davis
- Comprehensive Cancer Center, Department of Internal medicine, University of Michigan, Ann Arbor, MI, USA
| | - N Tawakkol
- Comprehensive Cancer Center, Department of Internal medicine, University of Michigan, Ann Arbor, MI, USA
| | - S G Clouthier
- Comprehensive Cancer Center, Department of Internal medicine, University of Michigan, Ann Arbor, MI, USA
| | - F Malik
- 1] Comprehensive Cancer Center, Department of Internal medicine, University of Michigan, Ann Arbor, MI, USA [2] Department of Cancer Pharmacology, Indian Institute of Integrative Medicine, Jammu, India
| | - A K Paulson
- Comprehensive Cancer Center, Department of Internal medicine, University of Michigan, Ann Arbor, MI, USA
| | - R C D'Angelo
- Comprehensive Cancer Center, Department of Internal medicine, University of Michigan, Ann Arbor, MI, USA
| | - S Korkaya
- Comprehensive Cancer Center, Department of Internal medicine, University of Michigan, Ann Arbor, MI, USA
| | - T L Baker
- Comprehensive Cancer Center, Department of Internal medicine, University of Michigan, Ann Arbor, MI, USA
| | - E S Esen
- Comprehensive Cancer Center, Department of Internal medicine, University of Michigan, Ann Arbor, MI, USA
| | - A Prat
- Translational Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - S Liu
- Comprehensive Cancer Center, Department of Internal medicine, University of Michigan, Ann Arbor, MI, USA
| | - C G Kleer
- Department of Pathology, University of Michigan Medical School, Ann Arbor, USA
| | - D G Thomas
- Department of Pathology, University of Michigan Medical School, Ann Arbor, USA
| | - M S Wicha
- Comprehensive Cancer Center, Department of Internal medicine, University of Michigan, Ann Arbor, MI, USA
| | - H Korkaya
- Comprehensive Cancer Center, Department of Internal medicine, University of Michigan, Ann Arbor, MI, USA
| |
Collapse
|
18
|
Dijcker JC, Hagen-Plantinga EA, Thomas DG, Queau Y, Biourge V, Hendriks WH. The effect of dietary hydroxyproline and dietary oxalate on urinary oxalate excretion in cats. J Anim Sci 2013. [DOI: 10.2527/jas.2012-6178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Paoletti C, Li Y, Muñiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson V, Irvin WJ, Lin NU, Liu M, Nanda R, Nangia J, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero A, Hayes DF. Abstract P1-04-01: Significance of circulating tumor cells in metastatic triple negative breast cancer: Results of an open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 tigatuzumab (TBCRC 019). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-04-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Circulating Tumor cells (CTCs) are prognostic at baseline and first follow-up in patients with metastatic breast cancer (MBC). Using the most commonly used assay (CellSearch®), we have previously reported the ability to detect apoptotic vs. non-apoptotic CTCs in patients with MBC. However, there has been concern regarding the performance of the CellSearch® assay in patients with triple negative (TN) MBC. We hypothesized that CellSearch® is an effective assay in patients with TN MBC, and that CTC-apoptosis might further separate prognosis. Therefore, we studied CTCs in patients with TN MBC who participated in a prospective randomized phase II trial testing for activity of tigatuzumab (TIG) in combination with nanoparticle albumin-bound paclitaxel (nab-PAC) conducted by the Translational Breast Cancer Research Consortium (overall results reported by Forero A., et al, ASCO 2013).
Methods: Whole blood (WB) was drawn into a CellSave tube at baseline, day 15, and day 29 and CTC counts were determined using the CXC CellSearch® kit. Apoptosis was characterized by staining with a monoclonal antibody that detects a neo-epitope on fragmented cytokeratin (M-30) and independently by visual inspection (nucleic condensation and/or fragmentation, as well as granular cytokeratin). Association between levels of CTCs and CTC-apoptosis with the overall response rate (ORR) and progression free survival (PFS) at baseline, day 15, and day 29 was assessed using logistic regression, Kaplan Meier curves, and Cox proportional hazards modeling.
Results: Of the 60 patients entered into the trial, 52 were evaluable for CTCs. Of these, 19/52 (36.5%), 14/52 (26.9%), and 13/49 (26.5%) had elevated CTCs (≥5CTC/7.5 ml WB) at baseline, day 15, and day 29, respectively. Patients with elevated CTCs at each time point had worse PFS than patients with low or no CTCs. Hazard rates (HR) at baseline, day 15, and day 29 were 2.38 (95% CI: 1.27-4.45, p = 0.007), 2.87 (95% CI: 1.46-5.66, p = 0.002), and 3.40 (95% CI: 1.68-6.89, p = 0.001), respectively. The odds of overall response for those who had elevated CTCs compared to those who did not at baseline, day 15, and day 29, were 0.25 (95% CI: 0.073-0.81, p = 0.024), 0.18 (95% CI: 0.04-0.67, p = 0.014), and 0.06 (95% CI: 0.01-0.28, p = 0.001), respectively. There was no apparent prognostic effect comparing the degree of CTC-apoptosis vs. non-apoptosis.
Conclusions: Similar to observations in other intrinsic subgroups, CTCs were detected in a large fraction of TN MBC patients at baseline using CellSearch® assay, and reductions in CTC levels reflected response. In these homogenously prospectively enrolled TN MBC patients, regardless of treatment, CTCs are prognostic at baseline, day 15, and day 29. It does not appear that analysis of CTC-apoptosis is prognostic.
Supported by Susan G. Komen for the Cure, Veridex, LLC, Fashion Footwear Charitable Foundation of New York/QVC Presents Shoes on Sale™ (DFH), Associazione Sandro Pitigliani and by a studentship from FIRC (CP), Triple Negative Breast Cancer Foundation, The AVON Foundation, and The Breast Cancer Research Foundation.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-04-01.
Collapse
Affiliation(s)
- C Paoletti
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - Y Li
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - MC Muñiz
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - KM Kidwell
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - K Aung
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - DG Thomas
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - ME Brown
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - V Abramson
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - WJ Irvin
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - NU Lin
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - M Liu
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - R Nanda
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - J Nangia
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - AM Storniolo
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - TA Traina
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - C Vaklavas
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - CH Van Poznak
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - AC Wolff
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - A Forero
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| | - DF Hayes
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Vanderbilt Breast Cancer Center One Hundred Oaks, Nashville, TN; Bon Secours Cancer Institute, Midlothian, VA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York City, NY; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
| |
Collapse
|
20
|
Paoletti C, Muñiz MC, Aung K, Larios J, Thomas DG, Tokudome N, Brown ME, Connelly MC, Chianese DA, Schott AF, Henry NL, Rae JM, Hayes DF. Abstract PD6-4: Heterogeneity of expression of estrogen receptor by circulating tumor cells suggests diverse mechanisms of resistance to fulvestrant in metastatic breast cancer patients. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-pd6-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Fulvestrant is a selective estrogen receptor down-regulator (SERD). Recent studies have shown that the efficacy of fulvestrant is dose-related. However, at the higher dose (500 mg/month) most cancers develop resistance and progress. We previously reported expression of several markers, including estrogen receptor (ER) and BCL-2, on breast cancer circulating tumor cells (CTC) using CellSearch®. We now report pilot data showing inter-patient heterogeneity of these markers on CTC in patients with known ER positive breast cancer whose disease is progressing on fulvestrant.
Methods: We conducted a pilot trial to determine the analytical validity of measuring expression of markers of endocrine sensitivity (ER, BCL-2) or resistance (HER-2, Ki-67) with fluorescent-labeled antibodies using the CellSearch® system. Patients with ER positive metastatic breast cancer (MBC) whose disease was progressing on any type of therapy were eligible after signed informed consent. This report is limited to the subjects who were progressing on fulvestrant. Whole blood (WB) was characterized for CTC counts and each of the four molecular markers using the CXC CellSearch® kit.
Results: Of 50 enrolled patients, seven were progressing on fulvestrant. Two patients had no detectable CTC, while five patients had an average of ≥5 CTC/7.5 mL WB. Results are shown in a table below:
CTC-ERCTC-BCL-2Patient #Fulvestrant dose (mg/month)Days since last doseN CTC/7.5 mL of WB% of CTC-ER+N CTC/7.5 mL of WB% of CTC-BCL-2+295002880%110%4550028170%170%2250341010%714%850031812%1735%172507728%367%
These exploratory data suggest widely different mechanisms of resistance to fulvestrant in different patients with ER positive MBC. In two of the patients (29, 45) treated with 500 mg/month, both CTC-ER and CTC-BCL-2 expression were absent, suggesting no signaling through the ER pathway. We hypothesize either that fulvestrant was actively down-regulating ER, but the cancers had adopted other growth and survival pathways, or that ER negative, hormone-independent clones had evolved. In the other three cases, ER was clearly present with evidence of signaling, based on BCL-2 expression. Two of these patients (2, 17) were on the lower dose of fulvestrant, now considered to be less effective. However, the third (8) was on the higher dose and yet still had evidence of ER signaling. This observation suggests that some patients may benefit from even higher doses of SERD therapy.
Conclusions: These pilot results suggest heterogeneous biological or pharmacological mechanisms of resistance to SERD therapy. These data suggest that CTC-ER and CTC-BCL-2 expression could serve as pharmacodynamic monitoring tools for dose escalation of fulvestrant or other SERDs. Further molecular analysis might provide biological bases for resistance to fulvestrant.
Supported by Veridex, LLC, Fashion Footwear Charitable Foundation of New York/QVC Presents Shoes on Sale™ (DFH), Associazione Sandro Pitigliani and by a studentship from FIRC (CP).
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr PD6-4.
Collapse
Affiliation(s)
- C Paoletti
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - MC Muñiz
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - K Aung
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - J Larios
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - DG Thomas
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - N Tokudome
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - ME Brown
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - MC Connelly
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - DA Chianese
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - AF Schott
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - NL Henry
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - JM Rae
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| | - DF Hayes
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Veridex, LLC, Huntingdon Valley, PA
| |
Collapse
|
21
|
Abstract
The apparent total tract and ileal digestibility assays to measure AA absorption in commercial canine diets were compared in the present study. Five ileal cannulated dogs were fed 5 commercial dry canine foods selected to contain 19 to 30% CP in a 5 × 5 Latin square design. Ileal and total tract digestibility (apparent and standardized) of DM, OM, CP, crude fat (CF), carbohydrate, and AA (including reactive Lys) were calculated using Cr2O3 as an indigestible marker. Greater apparent total tract digestibility values were found for DM, OM, and CP (P ≤ 0.034) compared with ileal digestibility values; however, CF (P = 0.058) had a greater ileal apparent digestibility. Apparent and standardized CP digestibility values were, respectively, 5.7 and 7.4 percentage units greater when measured over the total digestive tract compared with measurement at the ileum (P = 0.034 and 0.011, respectively). Ileal apparent digestibility for N of AA (P = 0.009) and most AA (P < 0.05), except for Met, Ile, Lys, Phe, and Ala, was decreased if measured at the ileum. However, correction for endogenous losses showed only Met digestibility did not differ between measurement sites. Differences between sites in excess of 15 percentage units were recorded for AA. Apparent and standardized ileal reactive Lys digestibility was 3.1 to 15.3 percentage units greater than corresponding total tract digestibility values. For several indispensable AA, the bioavailability estimates currently used by the 2006 NRC and the 2011 Association of American Feed Control Officials to derive allowance estimates for canine adult maintenance were greater than the digestibility values of these AA in the commercial dog foods evaluated. Although the canine large intestine is relatively short, the total tract digestibility assay in dogs can overestimate the digestibility of dietary AA and CP and may not be an accurate method for the measurement of absorption. In this study, bioavailability estimates of AA appeared to be less than those used to derive allowance estimates for commercial dog foods. Further work is required if current recommendations warrant adjustment.
Collapse
Affiliation(s)
- W H Hendriks
- Animal Nutrition Group, Wageningen University, 6700 AH, Wageningen, The Netherlands.
| | | | | | | |
Collapse
|
22
|
Whitehouse-Tedd KM, Cave NJ, Ugarte CE, Waldron LA, Prasain JK, Arabshahi A, Barnes S, Hendriks WH, Thomas DG. Isoflavone metabolism in domestic cats (Felis catus): comparison of plasma metabolites detected after ingestion of two different dietary forms of genistein and daidzein. J Anim Sci 2013; 91:1295-306. [PMID: 23307849 DOI: 10.2527/jas.2011-4812] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Some felid diets contain isoflavones but the metabolic capacity of cats toward isoflavones is relatively unknown, despite the understanding that isoflavones have divergent biological potential according to their metabolite end products. The objective of this study was to determine the plasma metabolites detectable in domestic cats after exposure to 2 different dietary forms of isoflavones, either as a soy extract tablet (n = 6) or as part of a dietary matrix (n = 4). Serial blood samples were collected after isoflavone exposure to identify the plasma metabolites of each cat. Genistein was detected in its unconjugated form or as a monosulfate. Daidzein was detected as both a mono- and disulfate as well as in its unconjugated form. Other daidzein metabolites detected included equol mono- and disulfate, dihydrodaidzein, and O-desmethylangolensin. No β-glucuronide metabolites of either isoflavone were detected. Equol was produced in markedly fewer cats after ingestion of a soy extract tablet as a single oral bolus compared with cats consuming an isoflavone-containing diet. The detectable metabolites of the isoflavones, genistein and daidzein, in domestic cat plasma after dietary ingestion has been described in the present study for the first time. The metabolic capacity for isoflavones by domestic cats appears to be efficient, with only minimal proportions of the ingested amount detected in their unconjugated forms. This has implications for the potential of isoflavones to exert physiological activity in the domestic cat when consumed at concentrations representative of typical dietary intake.
Collapse
Affiliation(s)
- K M Whitehouse-Tedd
- Center for Feline Nutrition, Institute of Food, Nutrition, and Human Health, Massey University, Palmerston North, 4410, New Zealand.
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Bermingham EN, Weidgraaf K, Hekman M, Roy NC, Tavendale MH, Thomas DG. Seasonal and age effects on energy requirements in domestic short-hair cats (Felis catus) in a temperate environment. J Anim Physiol Anim Nutr (Berl) 2012; 97:522-30. [PMID: 22530814 DOI: 10.1111/j.1439-0396.2012.01293.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
There is little information known about the energy requirements of cats in temperature climates. Energy requirement of domestic short-haired cats was determined using three groups of mixed gender - old kept outside (approximately 9.9 years of age; 4.8 kg; n = 9), young kept outside (approximately 3.1 years of age; 3.9 kg; n = 8) or young kept inside (approximately 3.1 years of age; 3.9 kg; n = 8). Cats were housed individually for 5 weeks during summer (18.5 ± 0.5 °C) and winter (8.5 ± 0.4 °C) and were fed a commercially available maintenance diet ad libitum. In both periods, energy expenditure was determined from the rates of (2) H and (18) O elimination for blood H2 O over a 12 day period, from a doubly labelled water bolus (2) H2 O (0.7 g/kg BW) and H2 (18) O (0.13 g/kg BW) administered intravenously. During the summer period, macronutrient digestibility was determined. Older cats had a reduction (p < 0.05) in apparent digestibility of dry matter (approximately 9%), energy (approximately 8%) and protein (6%). There was a significant effect of age and season on energy intake and energy expenditure. While lean mass was affected by age and season, there was no effect of age or season on energy expenditure when expressed as a proportion of lean mass. Possible seasonal differences in nutrient digestibility may explain these results.
Collapse
Affiliation(s)
- E N Bermingham
- Food Nutrition Health Team, Food & Bio-Based Products Group, AgResearch, Grasslands, New Zealand.
| | | | | | | | | | | |
Collapse
|
24
|
Todd SE, Thomas DG, Bosch G, Hendriks WH. Selenium status in adult cats and dogs fed high levels of dietary inorganic and organic selenium. J Anim Sci 2012; 90:2549-55. [PMID: 22307479 DOI: 10.2527/jas.2011-3911] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Cats (Felis catus) maintain greater blood Se concentrations compared with dogs (Canis familiaris) and, unlike dogs, show no signs of chronic Se toxicity (selenosis) when fed dietary organic Se (selenomethionine) concentrations of 10 μg/g DM. This study investigated the response of cats and dogs to high dietary concentrations of sodium selenite and organic Se to determine differences in metabolism between both species. In 2 consecutive studies, 18 adult cats and 18 adult dogs of with equal numbers of each sex were fed a control diet (0.6 μg Se/g DM) or the control diet supplemented to 8 to 10 μg Se/g DM from Na(2)SeO(3) or organic Se for 3 wk. All animals were fed the control diet 1 mo before the start of the study and blood samples were taken on d 0 and 21. The Se balance was assessed during the final week and a liver biopsy was obtained on the final day of the study. Measurements included plasma Se concentrations, plasma glutathione peroxidise (GPx) activities, plasma Se clearance, Se intake, and urinary Se excretion. No clinical signs of selenosis were observed in the cats or dogs, and apart from Se clearance, form of Se had no effect on any of the measurements. Apparent fecal Se absorption was greater in the dogs fed both forms of Se, while greater plasma Se concentrations were observed in the cats on both the control and supplemented diet (P = 0.034). Cats fed the supplemented diets had lower hepatic Se concentrations (P < 0.001) and excreted more Se in urine (P < 0.001) compared with dogs. Furthermore, cats fed the Na(2)SeO(3) supplement had greater Se clearance rates than dogs (P < 0.001). There was no effect of species on plasma GPx activity. We conclude that cats can tolerate greater dietary Se concentrations as they are more efficient at excreting excess Se in the urine and storing less Se in the liver.
Collapse
Affiliation(s)
- S E Todd
- Institute of Food, Nutrition and Human Health, Massey University, Palmerston North, New Zealand.
| | | | | | | |
Collapse
|
25
|
Luker KE, Lewin SA, Mihalko LA, Schmidt BT, Winkler JS, Coggins NL, Thomas DG, Luker GD. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene 2012; 31:4750-8. [PMID: 22266857 PMCID: PMC3337948 DOI: 10.1038/onc.2011.633] [Citation(s) in RCA: 163] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Chemokine CXCL12 and receptor CXCR4 control multiple steps in primary tumor growth and metastasis in breast cancer and more than 20 other human malignancies. Mechanisms that regulate availability of CXCL12 in tumor microenvironments will substantially impact cancer progression and ongoing efforts to target the CXCL12-CXCR4 pathway for cancer chemotherapy. We used dual luciferase imaging to investigate CXCR7 dependent scavenging of CXCL12 in breast tumors in vivo and quantify effects of CXCR7 on tumor growth and metastasis of a separate population of CXCR4+ breast cancer cells. In a mouse xenograft model of human breast cancer, in vivo imaging showed that malignant cells expressing CXCR7 reduced bioluminescent CXCL12 secreted in the primary tumor microenvironment. Capitalizing on sensitive detection of bioluminescent CXCL12, we also demonstrated that CXCR7+ cells reduced amounts of chemokine released from orthotopic tumors into the circulation. Immunofluorescence staining of human primary breast cancers showed expression of CXCR4 and CXCR7 on malignant cells in ≈ 30% of cases. In most cases, CXCR4 and CXCR7 predominantly were expressed on separate populations of malignant cells in a tumor. We modeled these cases of human breast cancer by co-implanting tumor xenografts with CXCR4+ breast cancer cells, human mammary fibroblasts secreting CXCL12, and CXCR7+ or control breast cancer cells. Bioluminescence imaging showed that CXCR7+ breast cancer cells enhanced proliferation of CXCR4+ breast cancer cells in orthotopic tumors and spontaneous metastases. Treatment with a small molecule inhibitor of CXCR7 chemokine scavenging limited growth of CXCR4+ breast cancer cells in tumors that also contained malignant CXCR7+ cells. These studies establish a new in vivo imaging method to quantify chemokine scavenging by CXCR7 in the tumor microenvironment and identify that CXCR7+ cells promote growth and metastasis of CXCR4+ breast cancer cells.
Collapse
Affiliation(s)
- K E Luker
- Center for Molecular Imaging, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109-2200, USA
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Cheong SH, Kim KH, Jeon BT, Park PJ, Hwang IH, Choi NJ, Kim ET, Hong SK, Park JH, Sung SH, Thomas DG, Moon SH. Effect of mulberry silage supplementation during late fattening stage of Hanwoo (Bos taurus coreanae) steer on antioxidative enzyme activity within the longissimus muscle. Anim Prod Sci 2012. [DOI: 10.1071/an11087] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
This study was conducted to determine the possible application of mulberry silage as a functional feed in the feeding management of Hanwoo, Korean native cattle, for high quality beef production. Twenty Hanwoo steers in the last stage of fattening were randomly assigned to two groups with (MSS) or without (Control) supplemental mulberry silage. The Control group was fed on a standard total mixed commercial ration, while the MSS group was fed on a total mixed commercial ration formulated with mulberry silage at the rate of 10%, fresh matter basis, for 30 days. The mulberry silage contained active ingredients such as 1-deoxynojirimycin, γ-aminobutyric acid, and phenol compounds. In the present study, the oxidative stress biomarkers such as glutathione, superoxide dismutase, glutathione peroxidase, catalase, and glutathione-S-transferase were improved in the MSS group compared with the Control group. Electron spin resonance assays showed that 1,1-diphenyl-2-picrylhydrazyl radical scavenging activity was significantly elevated by 75.5% in the MSS group (P < 0.001). Moreover, the MSS group exhibited stronger scavenging activity against hydroxyl radicals, superoxide radicals, and alkyl radicals, and the radical scavenging activity occurred in a dose-dependent manner. Findings from the present study suggest that mulberry silage may be useful as a functional feed by improving the antioxidant activity against various reactive radicals for beef cattle.
Collapse
|
27
|
Paoletti C, Connelly MC, Chianese DA, Brown ME, Muñiz MC, Rae JM, Thomas DG, Hayes DF. P4-07-16: Development of Circulating Tumor Cell-Endocrine Therapy Index in Metastatic Breast Cancer Patients. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-07-16] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Only ∼ 50% of patients (pts) with estrogen receptor (ER) positive metastatic breast cancer (MBC) benefit from endocrine therapy (ET). Currently only clinical judgment can be used to identify pts with endocrine-refractory MBC, who are better palliated with chemotherapy. Circulating Tumor Cells (CTC) are reliably enumerated using an automated immunomagnetic system (CellSearch®; Veridex LLC). High CTC levels predict rapid progression in pts with MBC. We have developed a multi-parameter assay, the CTC-Endocrine Therapy Index (CTC-ETI) using CellSearch® that may identify pts with ER positive MBC who are unlikely to benefit from ET and may be better served with chemotherapy. CTC-ETI scores are assigned based on CTC levels coupled with the relative percent and degree of marker positivity on the CTC. We report preliminary results from a pilot single institutional study.
Methods: CellSearch® has 4 fluorescence channels. Three distinguish CTC from WBC (DAPI, anti-cytokeratin, anti-CD45). The 4th “empty” channel was used to measure ER, BCL-2, HER-2, and Ki-67 expression with fluorescent-labeled antibodies. These 4 markers reflect sensitivity (ER, BCL-2) or resistance (HER-2, Ki-67) to ET. Forty ml of blood was drawn into 4 CellSave® tubes from pts with progressive MBC. Whole blood from 4 tubes was pooled and divided into 4 different 7.5 ml aliquots of blood, which were processed and characterized for CTC counts and each of the four molecular markers using the CXC CellSearch® kit.
Results: 21 pts have been accrued to the feasibility study. One patient was ineligible. Five of 20 pts had low CTC counts (<5 CTC/7.5ml whole blood), and are expected to have a relatively favorable prognosis. CTC-ETI was successfully determined in 10 pts (50%): 2 pts had low, while 3 had intermediate, and 5 had high CTC-ETI. Technical difficulties precluded accurate CTC-ETI in the remaining 5 patients. Of note, expression of the biomarkers among CTC in single patients was heterogeneous, suggesting that future iterations of the CTC-ETI will have to consider expression variability. Further exploratory results regarding associations between CTC-ETI and outcomes will be presented.
Conclusions: ER, BCL-2, HER-2, and Ki-67 can be accurately determined on CTC using the 4th channel in the CellSearch® system to calculate CTC-ETI. We predict that lower CTC-ETI scores (low or no CTC, or CTC with high CTC ER and BCL-2 and low CTC HER-2 and Ki-67) could be associated with favorable response to ET. Successful completion of the feasibility study will lead to a prospective trial to determine if high CTC-ETI at baseline predicts resistance and rapid progression on ET in women starting a new endocrine therapy for MBC.
Supported by Veridex, LLC, Fashion Footwear Charitable Foundation of New York/QVC Presents Shoes on Sale ™ (DFH), Associazione Sandro Pitigliani and by a studentship from FIRC (CP).
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-07-16.
Collapse
Affiliation(s)
- C Paoletti
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - MC Connelly
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - DA Chianese
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - ME Brown
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - MC Muñiz
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - JM Rae
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - DG Thomas
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| | - DF Hayes
- 1University of Michigan Comphrehensive Cancer Center, Ann Arbor, MI; Veridex, LLC a J.&J. Co., Huntingdon Valley, PA
| |
Collapse
|
28
|
Singh I, Tucker LA, Gendall P, Rutherfurd-Markwick KJ, Cline J, Thomas DG. Age, breed, sex distribution and nutrition of a population of working farm dogs in New Zealand: results of a cross-sectional study of members of the New Zealand Sheep Dog Trial Association. N Z Vet J 2011; 59:133-8. [PMID: 21541887 DOI: 10.1080/00480169.2011.567967] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
AIM To establish baseline information about age, breed, sex distribution and feeding practices for a population of working farm dogs owned by members of the New Zealand Sheep Dog Trial Association (NZSDTA) throughout New Zealand. METHODS Questionnaires were sent to members of the NZSDTA in August 2007, requesting information on the size and terrain of the farms where they worked, as well as the breed, weight, age and sex of each working dog they owned, feeding regime employed, diet fed, work levels, and general health of their dogs. RESULTS The survey was completed by 542/676 (81%) of the eligible sample population, and provided information on 2,861 dogs, excluding those <1 year old. All of the dog owners surveyed worked on sheep and beef-cattle farms. The median farm size was 440 [Inter-quartile range (IQR) 132-1,200] ha and varied with region. The majority of farms were situated on either hill country (184/542; 34%) or a mixture of hilly and flat terrain (260/542; 48%), and had a median of six (IQR 5-8) working dogs per farm. The median age of dogs was 3.0 (IQR 2.0-6.0) years. Heading dogs were the most common type of working dog (1,510/2,861; 52.8%), followed by Huntaways (1,161/2,861; 40.6%). The gender distribution of all dogs was biased towards males (57%), but this decreased with age. There was a positive association between the number of dogs on a farm and perceived level of tiredness of dogs (p<0.001), but there were no differences in levels of tiredness between farms of different terrain. Most owners (526/542; 97%) fed their dogs once a day. The most common diet fed was a combination of dry food and homekill, which was fed by 328/542 (61%) owners during peak and 313/542 (58%) during off-peak periods of work. CONCLUSIONS AND CLINICAL RELEVANCE This study has established baseline information on the age, breed, gender and nutrition of a large population of working farm dogs in New Zealand. Current feeding practices employed by owners include offering a substantial amount of homekill to their animals. Homekill may be deficient or marginal in vitamins and minerals, therefore opportunities could exist to improve the diets and therefore the longevity and performance of these dogs.
Collapse
Affiliation(s)
- I Singh
- Institute of Food, Nutrition and Human Health, College of Science, Massey University, Private Bag 11222, Palmerston North 4442, New Zealand
| | | | | | | | | | | |
Collapse
|
29
|
Todd SE, Thomas DG, Hendriks WH. Selenium balance in the adult cat in relation to intake of dietary sodium selenite and organically bound selenium. J Anim Physiol Anim Nutr (Berl) 2011; 96:148-58. [PMID: 21320178 DOI: 10.1111/j.1439-0396.2011.01132.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The response of cats to dietary sodium selenite (Na(2) SeO(3)) and organically bound selenium was studied in two separate studies with four cats per treatment and three levels of selenium supplementation (targets 1.0, 1.5 and 2.0 μg/g DM) for each Se source. Whole blood and plasma selenium concentrations and glutathione peroxidase (GPx) activity were determined at 7-time points across the 32-day study. Faeces were quantitatively collected during the last 8 days and urine was collected daily during both studies. The basal diet used had a low apparent faecal selenium absorption of 25.3 ± 3.0%. Daily faecal and urinary selenium excretion increased linearly with increasing selenium intake for both Se sources. Urinary selenium concentration of the cats fed the supplemented diets increased rapidly (∼2 days) and remained constant throughout the remainder of the study. Apparent faecal selenium absorption was high for both selenium sources (73.2% and 80.0%). Plasma, and to a lesser extent, whole blood selenium concentrations increased in a dose-dependent manner with supplementation. Whole blood and plasma GPx activity were highly variable and showed a variable response to dietary selenium intake. Cats closely regulate selenium homeostasis through increasing urinary excretion whilst faecal absorption remains unaffected.
Collapse
Affiliation(s)
- S E Todd
- Institute of Veterinary, Animal and Biomedical Sciences, Massey University, Palmerston North, New Zealand.
| | | | | |
Collapse
|
30
|
Maranci V, Thomas DG, Brown M, Budd TG, Doyle G, Hayes DF, Griffith KA, Smeage J. Abstract P3-02-06: Correlation of BCL-2 and Apoptosis on Circulating Tumor Cells and Breast Cancer Tissue. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p3-02-06] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Circulating Tumor Cell (CTC) levels are prognostic markers in metastatic breast cancer (MBC). Further phenotypic characterization of CTC may provide an opportunity for non-invasive evaluation of predictive and prognostic markers. Apoptosis is a common form of chemotherapy-induced cell death. Monoclonal antibody (MAb) M30 recognizes a neo-epitope on fragmented cytokeratin and is a marker of apoptosis. BCL-2 is an anti-apoptotic marker and may predict for resistance to anti-neoplastic therapy. We have previously reported the results of a pilot clinical trial to estimate M30 and BCL-2 expression in CTC from patients with MBC. The current study was performed to correlate the expression of both BCL-2 and M30 in CTC with breast cancer tissue samples. Methods: Of the 85 patients in the original pilot study, 52 (61%) had evaluable tissue available (39 primary and 12 metastatic lesions; one unknown) and were included in this analysis. CTC were collected at baseline and were isolated, enumerated, and phenotypically characterized for M30 and BCL-2 using the CellSearch® System. CTC phenotype is reported as percentage of cells with positive staining. Tissue Microarrays (TMA) were constructed and immunohistochemically stained for M30 (anti-Cytodeath™ M30, Roche) and Bcl-2 (M-0887, DAKO) and scored using the Allred method.
Results: Tissue staining for M30 and Bcl-2 were inversely correlated. Of the 52 patients with TMA available for investigation, 22 (42%) had > 5 CTC/7.5 ml whole blood. A positive, but non-significant, correlation was observed between increasing numbers of CTC levels and tissue BCL-2 Allred Score (Spearman r=0.36; p=0.1310). M30 staining was detected in ≥10% of CTC in 20 of the 22 (91%) patients with elevated CTC, while BCL-2 staining was detected in ≥10% of CTC in 19 of the 22 (86%) patients. Little if any correlation was observed between CTC M30 and tissue M30 expression, however CTC BCL-2 was positively correlated with tissue Bcl-2 expression (Spearman r=0.47; p=0.0440). Conclusions: BCL-2 and M30 can be characterized in both CTC and breast cancer tissue. The likelihood of having elevated CTC may be associated with higher BCL-2 expression, and CTC BCL-2 was associated with tissue BCL-2 expression. Although the clinical implications of these findings are unknown, they offer the opportunity for future trials to investigate whether CTC BCL-2 and M30 might be useful to identify patients with cancers that are resistant to standard therapies. Furthermore, CTC BCL-2 and M30 might be monitored in clinical trials of novel, apoptosis-inducing therapeutic agents.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P3-02-06.
Collapse
Affiliation(s)
- V Maranci
- University of Michigan, Ann Arbor; Cleveland Clinic, OH; Veridex LLC, Raritan, NJ
| | - DG Thomas
- University of Michigan, Ann Arbor; Cleveland Clinic, OH; Veridex LLC, Raritan, NJ
| | - M Brown
- University of Michigan, Ann Arbor; Cleveland Clinic, OH; Veridex LLC, Raritan, NJ
| | - TG Budd
- University of Michigan, Ann Arbor; Cleveland Clinic, OH; Veridex LLC, Raritan, NJ
| | - G Doyle
- University of Michigan, Ann Arbor; Cleveland Clinic, OH; Veridex LLC, Raritan, NJ
| | - DF Hayes
- University of Michigan, Ann Arbor; Cleveland Clinic, OH; Veridex LLC, Raritan, NJ
| | - KA Griffith
- University of Michigan, Ann Arbor; Cleveland Clinic, OH; Veridex LLC, Raritan, NJ
| | - J. Smeage
- University of Michigan, Ann Arbor; Cleveland Clinic, OH; Veridex LLC, Raritan, NJ
| |
Collapse
|
31
|
Karakoula K, Bigner DD, Keir S, Thomas DG, Darling J, Warr T, Al-Halabi H, Albrecht S, Guiot MC, Kelkner A, Sahebjam S, Kavan P, Freeman CR, Muanza T, Jabado N, Bielen A, Perryman L, Box G, Popov S, Jeay S, Hofmann F, Hargrave D, Eccles S, Jones C, Dubuc AM, Mack S, Nakahara Y, Garzia L, Northcott PA, Kongkham P, Baylin S, Watkins N, Taylor MD, Paugh BS, Qu C, Zhang J, Geyer JR, Chi S, da Silva NS, Baker J, Gajjar A, Ellison DW, Broniscer A, Baker SJ, Mainwaring LA, Taylor M, Dupuy A, Kenney AM, Williams SC, Zagzag D, Chiriboga L, Becher OC, von Deimling A, Allen JC, Karajannis MA, Stearns D, von Buren AO, Donson A, Foreman N, Eberhart C, Taylor P, Kang N, Das CM, Rajaram V, Aguilera DG, Goldman S, Fangusaro J, Gopalakrishnan V, Das CM, Taylor P, Su X, Kommagani R, Aguilera DG, Wolff JE, Kadakia MP, Flores ER, Gopalakrishnan V. Pediatrics Laboratory Research. Neuro Oncol 2010. [DOI: 10.1093/neuonc/noq116.s12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Ilhan A, Wagner L, Maj M, Woehrer A, Czech T, Heinzl H, Marosi C, Base W, Preusser M, Jeuken JW, Navis AC, Sijben A, Boots-Sprenger SH, Bleeker FE, Gijtenbeek JM, Wesseling P, Seyed Sadr E, Tessier A, Seyed Sadr M, Alshami J, Anan M, Sabau C, Del Maestro R, Agnihotri S, Gajadhar A, Wolf A, Mischel PM, Hawkins C, Guha A, Guan X, Chance MR, Barnholtz-Sloan JS, Larson JD, Rodriguez FJ, Demer AM, Sarver AL, Dubac A, Jenkins RB, Dupuy AJ, Copeland NG, Jenkins NA, Taylor MD, Largaespada DA, Lusis EA, Stuart JE, Scheck AC, Coons SW, Lal A, Perry A, Gutmann DH, Barnholtz-Sloan JS, Adams MD, Cohen M, Devine K, Wolinsky Y, Bambakidis N, Selman W, Miller R, Sloan AE, Suchorska B, Mehrkens JH, Eigenbrod S, Eroes CA, Tonn JC, Kretzschmar HA, Kreth FW, Buczkowicz P, Bartels U, Morrison A, Zarghooni M, Bouffet E, Hawkins C, Kollmeyer TM, Wrensch M, Decker PA, Xiao Y, Rynearson AL, Fink S, Kosel ML, Johnson DR, Lachance DH, Yang P, Fridley BL, Wiemels J, Wiencke J, Jenkins RB, Zhou YH, Hess KR, Yu L, Raj VR, Liu L, Alfred Yung WK, Hutchins LF, Linskey ME, Roldan G, Kachra R, McIntyre JB, Magliocco A, Easaw J, Hamilton M, Northcott PA, Van Meter T, Eberhart C, Weiss W, Rutka JT, Gupta N, Korshunov A, French P, Kros J, Michiels E, Kloosterhof N, Hauser P, Montange MF, Jouvet A, Bouffet E, Jung S, Kim SK, Wang KC, Cho BK, Di Rocco C, Massimi L, Leonard J, Scheurlen W, Pfister S, Robinson S, Yang SH, Yoo JY, Cho DG, Kim HK, Kim SW, Lee SW, Fink S, Kollmeyer T, Rynearson A, Decker P, Sicotte H, Yang P, Jenkins R, Lai A, Kharbanda S, Tran A, Pope W, Solis O, Peale F, Forrest W, Purjara K, Carrillo J, Pandita A, Ellingson B, Bowers C, Soriano R, Mohan S, Yong W, Aldape K, Mischel P, Liau L, Nghiemphu P, James CD, Prados M, Westphal M, Lamszus K, Cloughesy T, Phillips H, Thon N, Kreth S, Eigenbrod S, Lutz J, Ledderose C, Tonn JC, Kretzschmar H, Kreth FW, Mokhtari K, Ducray F, Kros JM, Gorlia T, Idbaih A, Marie Y, Taphoorn M, Wesseling P, Brandes AA, Hoang-Xuan K, Delattre JY, Van den Bent M, Sanson M, Lavon I, Shahar T, Granit A, Smith Y, Nossek E, Siegal T, Ram Z, Marko NF, Quackenbush J, Weil RJ, Ducray F, Criniere E, Idbaih A, Paris S, Marie Y, Carpentier C, Houillier C, Dieme M, Adam C, Hoang-Xuan K, Delattre JY, Duyckaerts C, Sanson M, Mokhtari K, Zinn PO, Kozono D, Kasper EM, Warnke PC, Chin L, Chen CC, Saito K, Mukasa A, Saito N, Stieber D, Lenkiewicz E, Evers L, Vallar L, Bjerkvig R, Barrett M, Niclou SP, Gorlia T, Brandes A, Stupp R, Rampling R, Fumoleau P, Dittrich C, Campone M, Twelves C, Raymond E, Lacombe D, van den Bent MJ, Potter N, Ashmore S, Karakoula K, Ward S, Suarez-Merino B, Luxsuwong M, Thomas DG, Darling J, Warr T, Gutman DA, Cooper L, Kong J, Chisolm C, Van Meir EG, Saltz JH, Moreno CS, Brat DJ, Brennan CW, Brat DJ, Aldape KD, Cohen M, Lehman NL, McLendon RE, Miller R, Schniederjan M, Vandenberg SR, Weaver K, Phillips S, Pierce L, Christensen B, Smith A, Zheng S, Koestler D, Houseman EA, Marsit CJ, Wiemels JL, Nelson HH, Karagas MR, Wrensch MR, Kelsey KT, Wiencke JK, Al-Nedawi K, Meehan B, Micallef J, Guha A, Rak J. -Omics and Prognostic Markers. Neuro Oncol 2010. [DOI: 10.1093/neuonc/noq116.s8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
Abstract
Forty mixed-breed cats completed a parallel-group, clinical study to compare supragingival plaque accumulation using a triangular or rectangular shaped dry-expanded diet, with or without an anti-calculus agent (sodium tripolyphosphate) or an anti-plaque agent (plaque-reducing nutrient). The cats were divided into 4 equal groups based on plaque scores. Results showed that coating the kibble with sodium tripolyphosphate had no effect on plaque accumulation. Increasing the surface area and volume and changing the shape of the kibble was associated with a reduction in plaque accumulation, and coating the kibble with a plaque-reducing nutrient further reduced plaque accumulation. The importance of a combination of both mechanical abrasion (chewing) and chemical interference (plaque-reducing nutrient) was demonstrated in this study.
Collapse
Affiliation(s)
- DE Clarke
- From Massey University, Feline Unit, Palmerston North, New Zealand (Clarke, Thomas, Weidgraaf); Royal Canin Research Centre, Aimargues, France (Servet, Biourge); and, Wageningen University, Wageningen, The Netherlands (Hendriks)
| | - E Servet
- From Massey University, Feline Unit, Palmerston North, New Zealand (Clarke, Thomas, Weidgraaf); Royal Canin Research Centre, Aimargues, France (Servet, Biourge); and, Wageningen University, Wageningen, The Netherlands (Hendriks)
| | - W Hendriks
- From Massey University, Feline Unit, Palmerston North, New Zealand (Clarke, Thomas, Weidgraaf); Royal Canin Research Centre, Aimargues, France (Servet, Biourge); and, Wageningen University, Wageningen, The Netherlands (Hendriks)
| | - DG Thomas
- From Massey University, Feline Unit, Palmerston North, New Zealand (Clarke, Thomas, Weidgraaf); Royal Canin Research Centre, Aimargues, France (Servet, Biourge); and, Wageningen University, Wageningen, The Netherlands (Hendriks)
| | - K Weidgraaf
- From Massey University, Feline Unit, Palmerston North, New Zealand (Clarke, Thomas, Weidgraaf); Royal Canin Research Centre, Aimargues, France (Servet, Biourge); and, Wageningen University, Wageningen, The Netherlands (Hendriks)
| | - VC Biourge
- From Massey University, Feline Unit, Palmerston North, New Zealand (Clarke, Thomas, Weidgraaf); Royal Canin Research Centre, Aimargues, France (Servet, Biourge); and, Wageningen University, Wageningen, The Netherlands (Hendriks)
| |
Collapse
|
34
|
Hill SR, Rutherfurd-Markwick KJ, Ravindran G, Ugarte CE, Thomas DG. The effects of the proportions of dietary macronutrients on the digestibility, post-prandial endocrine responses and large intestinal fermentation of carbohydrate in working dogs. N Z Vet J 2009; 57:313-8. [DOI: 10.1080/00480169.2009.64718] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
35
|
Panchmatia JR, Arvin B, Thomas DG. Meningioma--an unusual cause of a forehead lump. Acta Neurochir (Wien) 2008; 150:925-6; discussion 926. [PMID: 18726059 DOI: 10.1007/s00701-008-0003-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2007] [Accepted: 12/12/2007] [Indexed: 10/21/2022]
Abstract
CASE REPORT A patient presenting with a forehead lump secondary to an intraosseous meningioma is described. In addition, diagnosis and management of meningiomata are discussed.
Collapse
|
36
|
Layman RM, Thomas DG, Sabel MS, Griffith KA, El-Ashry D, Schott AF. Assessment of estrogen receptor expression by automated quantitative analysis in core biopsy and surgical specimens in ER negative, HER-2 positive breast cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.11503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Ha HT, Chugh R, Griffith KA, Thomas DG, Schuetze SM, Lucas DR, Biermann JS, Zalupski MM. Phase II trial of cetuximab in patients (pts) with metastatic and/or locally advanced soft tissue and bone sarcomas. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.10537] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Thomas DG, Sureshkumar R, Khomami B. Pattern formation in Taylor-Couette flow of dilute polymer solutions: dynamical simulations and mechanism. Phys Rev Lett 2006; 97:054501. [PMID: 17026104 DOI: 10.1103/physrevlett.97.054501] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/20/2006] [Indexed: 05/12/2023]
Abstract
We report spatiotemporal pattern formation in Taylor-Couette flow (i.e., flow between rotating cylinders) of viscoelastic dilute polymer solutions obtained for the first time from first-principles dynamical simulations. Solution structures with varying spatial and temporal symmetries, such as rotating standing waves, flames, disordered oscillations, and solitary vortex solutions which include diwhirls (stationary and axisymmetric) and oscillatory strips (axisymmetric or nonaxisymmetric), are observed, depending on the ratio of fluid relaxation time to the time period of inner cylinder rotation. The flow-microstructure coupling mechanisms underlying the pattern formation process are also discussed.
Collapse
Affiliation(s)
- D G Thomas
- Department of Chemical Engineering and the Center for Materials Innovation, Washington University, St. Louis, MO 63130, USA
| | | | | |
Collapse
|
39
|
Chugh R, Maki RG, Thomas DG, Reinke D, Wathen JK, Patel S, Priebat DA, Meyers PA, Benjamin RS, Baker LH. A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.9515] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9515 Background: Aggressive fibromatosis (desmoid tumors, AF) are uncommon, locally aggressive, connective tissue neoplasms. Existing literature on systemic treatment of AF is sparse and consists mostly of case reports and small case-series. Based on previous observation of regression of AF treated with IM and tumoral expression of IM targets, SARC (Sarcoma Alliance for Research through Collaboration) included the treatment of AF onto a multi-institution phase II trial of IM in sarcoma. Here we report early clinical and laboratory results of the AF group. Methods: Eligible patients had histologically proven AF, unresectable or difficult to resect without considerable functional impairment. Patients were treated with IM 300 mg po BID (BSA≥1.5m2). The primary endpoint was complete (CR) or partial response(PR) at two months or stable disease (SD) or better at four months. Tumor DNA was extracted from available formalin fixed paraffin embedded tissue specimens and analyzed via allelic PCR and genomic DNA sequence analysis for specific point mutations in PDGFRα exons 12/14/18, PDGFRβ exons 12/18, KIT exons 9/11/13/17, and bRAF. Results: 51 patients were enrolled from 10/02 to 12/05 at 5 institutions, with 45 patients currently evaluable. The median age is 37 (range 14–67), and median number of prior therapies is 1 (range 0–3). 36 patients (80%) reached the primary endpoint of CR/PR at 2 months or SD or better at 4 months. The median time to treatment failure is 6.8 months (95% C.I. 5.8–17.1). Thus far, the maximum change in the largest dimension of the tumor ranged from a 21% increase to a 45% decrease. In 22 available tumor specimens, deletions within PDGFRαE12 and E18 were noted in 1 and 3 patients, respectively, while a wildtype genotype was found in other regions. Conclusions: IM has activity in AF, the mechanism of which remains unclear. While this is the largest reported phase II trial of AF, further improvement in evaluating clinical efficacy in this disease is clearly necessary. We plan an analysis of the maximum change in largest tumor dimension for each patient, which will be particularly beneficial in AF as responses often occur late. We have not as yet identified a laboratory predictor of clinical benefit. Further investigation of other potential targets in fresh tissue is warranted. [Table: see text]
Collapse
Affiliation(s)
- R. Chugh
- University of Michigan, Ann Arbor, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Washington Hospital Center, Washington, DC
| | - R. G. Maki
- University of Michigan, Ann Arbor, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Washington Hospital Center, Washington, DC
| | - D. G. Thomas
- University of Michigan, Ann Arbor, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Washington Hospital Center, Washington, DC
| | - D. Reinke
- University of Michigan, Ann Arbor, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Washington Hospital Center, Washington, DC
| | - J. K. Wathen
- University of Michigan, Ann Arbor, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Washington Hospital Center, Washington, DC
| | - S. Patel
- University of Michigan, Ann Arbor, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Washington Hospital Center, Washington, DC
| | - D. A. Priebat
- University of Michigan, Ann Arbor, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Washington Hospital Center, Washington, DC
| | - P. A. Meyers
- University of Michigan, Ann Arbor, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Washington Hospital Center, Washington, DC
| | - R. S. Benjamin
- University of Michigan, Ann Arbor, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Washington Hospital Center, Washington, DC
| | - L. H. Baker
- University of Michigan, Ann Arbor, MI; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Washington Hospital Center, Washington, DC
| |
Collapse
|
40
|
Miller CT, Lin L, Casper AM, Lim J, Thomas DG, Orringer MB, Chang AC, Chambers AF, Giordano TJ, Glover TW, Beer DG. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 2006; 25:409-18. [PMID: 16186806 DOI: 10.1038/sj.onc.1209057] [Citation(s) in RCA: 122] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Esophageal adenocarcinoma (EA) is characterized by a poor prognosis making the identification of clinically targetable proteins essential for improving patient outcome. We report the involvement of multiple alterations of the MET pathway in EA development and progression. Microarray analysis of Barrett's metaplasia, dysplasia, and EA revealed overexpression of the MET oncogene in EAs but only those with MET gene amplification. STS-amplification mapping revealed that the boundary of the MET amplicon in these EAs is defined by fragile site FRA7G. We also identified an amplicon at 11p13 that resulted in amplification and overexpression of CD44, a gene involved in MET autophosphorylation upon HGF stimulation. Tissue microarrays with phospho-MET-specific antibodies demonstrated a uniformly high abundance of MET activation in primary EA and cells metastatic to lymph nodes but to a lesser extent in a subset of metaplastic and dysplastic Barrett's samples. Increased expression of multiple genes in the MET pathway associated with invasive growth, for example, many MMPs and osteopontin, also was found in EAs. Treatment of EA-derived cell lines with geldanamycin, an inhibitor for tyrosine kinases including MET receptor kinase, reduced cell migration and induced EA cell apoptosis. The data indicate that upregulation of the MET pathway may contribute to the poor outcome of EA patients and that therapeutic agents targeting this pathway may help improve patient survival.
Collapse
Affiliation(s)
- C T Miller
- Department of Surgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Ravindran V, Wu YB, Thomas DG, Morel PCH. Influence of whole wheat feeding on the development of gastrointestinal tract and performance of broiler chickens. ACTA ACUST UNITED AC 2006. [DOI: 10.1071/ar05098] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The main aim of the present study was to investigate the changes in the relative growth of digestive organs of broilers as influenced by whole wheat feeding and age of birds. The secondary aim was to examine the effects of whole wheat feeding on broiler performance over a 5-week feeding period. Diets containing ground wheat and whole wheat (100 and 200 g/kg whole wheat replacing ground wheat during 1–21 days and 22–35 days, respectively) were placed in 4 replicate pens (46 birds/pen) each. Throughout the 5-week trial, the birds offered feed containing wheat as whole grain grew slower (P < 0.05) and consumed less (P < 0.05) feed than those offered feed containing ground wheat. Feed-to-gain ratio was not influenced (P > 0.05) by the form of wheat during the first 2 weeks, but was significantly lowered (P < 0.05) by whole wheat feeding from 3 weeks onwards. Over the 5-week period, the feed-to-gain ratio of birds fed the whole-wheat diet was 7 points better (P < 0.05) than of those fed the ground wheat diet. Improved feed efficiency from Week 3 onwards coincided with significant increases (P < 0.05) in the relative weights of the gizzard in birds fed the whole-wheat diet. Whole-wheat inclusion had no effect (P > 0.05) on the relative weights of crop, proventriculus, and pancreas or on the relative weight and length of the small intestine. The relative weights of storage sections of the gastrointestinal tract (crop, proventriculus, and gizzard) steadily declined during the 5-week period. The relative weights of pancreas and liver increased to Day 14 and decreased thereafter. The relative weights of intestinal segments were maximal during Weeks 1 and 2 of life, and declined rapidly with age. In general, the growth of different segments of the small intestine (duodenum, jejunum, and ileum) followed a similar pattern. The intestinal mass, measured as g tissue/cm tissue, steadily increased over the trial period, indicating that, although the relative size of the intestine declines with age, this decline is compensated by increased intestinal mass to support the nutrient supply function to the demand tissues.
Collapse
|
42
|
Thomas DG. An introduction to neurosurgery. 4th edition. B. Jennett and S. Galbraith. 215 × 140 mm. Pp. 360 + xi. Illustrated. 1983. London: William Heinemann. £17.00. Br J Surg 2005. [DOI: 10.1002/bjs.1800710940] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
43
|
Thomas DG. Bladder reconstruction and continent urinary diversion. L. R. King, A. R. Stone and G. D. Webster. 255 × 180 mm. Pp. 379 + xxi. Illustrated. 1987. London: Wolfe Medical Publications Ltd. £62.00. Br J Surg 2005. [DOI: 10.1002/bjs.1800741040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
44
|
Thomas DG. Urology for nurses. J. P. Mitchell. Third Edition. 184 × 121 mm. Pp. 359. Illustrated. 1980. Bristol: Wright. £6·50. Br J Surg 2005. [DOI: 10.1002/bjs.1800670728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
45
|
Ugarte CE, Thomas DG, Gasser RB, Hu M, Scott I, Collett MG. Spirometra erinacei / S. erinaceieuropaei in a feral cat in Manawatu with chronic intermittent diarrhoea. N Z Vet J 2005; 53:347-51. [PMID: 16220130 DOI: 10.1080/00480169.2005.36573] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
CASE HISTORY A feral cat captured in the Manawatu region of New Zealand was treated for worms and fleas, and kept confined in a metabolic cage. It showed good appetite and weight gain but had intermittent watery, yellow diarrhoea. CLINICAL FINDINGS Clinical examination under sedation was unremarkable and routine blood tests showed no significant abnormalities. The cat was negative for feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV). Different canned cat foods did not alter the course of the diarrhoea, and the cat was euthanised 6 months after capture. At necropsy, two sections of adult Spirometra tapeworms were found in the jejunum and typical Spirometra eggs were found in colonic contents. Molecular identification of the parasite was undertaken, using the cytochrome-c oxidase subunit-1 gene (cox1) sequence. DIAGNOSIS Chronic intermittent diarrhoea associated with Spirometra erinacei / S. erinaceieuropaei infection. CLINICAL RELEVANCE Spirometra has not been reported in New Zealand before but has been associated with gastrointestinal disease in cats in other parts of the world. It requires species targeted treatment to be eliminated effectively, and is zoonotic. Diagnosis could be difficult for clinicians who are not familiar with the parasite and its life cycle.
Collapse
Affiliation(s)
- C E Ugarte
- Institute of Food, Nutrition and Human Health, Massey University, Private Bag 11222, Palmerston North, New Zealand.
| | | | | | | | | | | |
Collapse
|
46
|
Chugh R, Thomas DG, Wagner T, Griffith K, Taylor J, Worden F, Schuetze S, Zalupski MM, Baker LH. Pharmacokinetics of ifosfamide and cytochrome P450 3A in a phase II trial of doxorubicin and ifosfamide in sarcoma patients. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.2035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Chugh
- Univ of Michigan Comprehensive Cancer Ctr, Ann Arbor, MI; Univ of Michigan, Ann Arbor, MI; Univ Hosp Luebeck, Luebeck, Germany
| | - D. G. Thomas
- Univ of Michigan Comprehensive Cancer Ctr, Ann Arbor, MI; Univ of Michigan, Ann Arbor, MI; Univ Hosp Luebeck, Luebeck, Germany
| | - T. Wagner
- Univ of Michigan Comprehensive Cancer Ctr, Ann Arbor, MI; Univ of Michigan, Ann Arbor, MI; Univ Hosp Luebeck, Luebeck, Germany
| | - K. Griffith
- Univ of Michigan Comprehensive Cancer Ctr, Ann Arbor, MI; Univ of Michigan, Ann Arbor, MI; Univ Hosp Luebeck, Luebeck, Germany
| | - J. Taylor
- Univ of Michigan Comprehensive Cancer Ctr, Ann Arbor, MI; Univ of Michigan, Ann Arbor, MI; Univ Hosp Luebeck, Luebeck, Germany
| | - F. Worden
- Univ of Michigan Comprehensive Cancer Ctr, Ann Arbor, MI; Univ of Michigan, Ann Arbor, MI; Univ Hosp Luebeck, Luebeck, Germany
| | - S. Schuetze
- Univ of Michigan Comprehensive Cancer Ctr, Ann Arbor, MI; Univ of Michigan, Ann Arbor, MI; Univ Hosp Luebeck, Luebeck, Germany
| | - M. M. Zalupski
- Univ of Michigan Comprehensive Cancer Ctr, Ann Arbor, MI; Univ of Michigan, Ann Arbor, MI; Univ Hosp Luebeck, Luebeck, Germany
| | - L. H. Baker
- Univ of Michigan Comprehensive Cancer Ctr, Ann Arbor, MI; Univ of Michigan, Ann Arbor, MI; Univ Hosp Luebeck, Luebeck, Germany
| |
Collapse
|
47
|
Wu YB, Ravindran V, Thomas DG, Birtles MJ, Hendriks WH. Influence of method of whole wheat inclusion and xylanase supplementation on the performance, apparent metabolisable energy, digestive tract measurements and gut morphology of broilers. Br Poult Sci 2004; 45:385-94. [PMID: 15327125 DOI: 10.1080/00071660410001730888] [Citation(s) in RCA: 108] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
1. The aim of the present study was to examine the influence of whole wheat inclusion and xylanase supplementation on the performance, apparent metabolisable energy (AME), digesta viscosity, and digestive tract measurements of broilers fed on wheat-based diets. The influence of the method of whole wheat inclusion (pre- or post-pelleting) was also compared. A 3 x 2 factorial arrangement of treatments was used with three diet forms (648 g/kg ground wheat [GW], GW replaced by 200 g/kg of whole wheat before [WW1] or after cold-pelleting [WW2]) and two xylanase levels (0 and 1000 XU/kg diet). 2. Birds given diets containing whole wheat had improved weight gains, feed efficiency and AME compared to those fed on diets containing ground wheat. The relative gizzard weight of birds fed WW2 diets was higher than in those fed GW and WW1 diets. Pre-pelleting inclusion of whole wheat had no effect on relative gizzard weight. Post-pelleting inclusion of whole wheat resulted in greater improvements in feed efficiency and AME than the pre-pelleting treatment. 3. Xylanase supplementation significantly improved weight gain, feed efficiency and AME, irrespective of the wheat form used. Viscosity of the digesta in the duodenum, jejunum and ileum were reduced by xylanase addition. Xylanase supplementation reduced the relative weight of the pancreas. 4. Neither xylanase supplementation nor whole wheat inclusion influenced the relative weight and length of the small intestine. 5. Xylanase supplementation increased ileal villus height. A significant interaction between diet form and xylanase was observed for ileal crypt depth. Xylanase supplementation had no effect on crypt depth in birds fed on diets containing GW, but increased the crypt depth in WW2 diets. No significant effects of diet form and xylanase supplementation were observed for the thickness of the tunica muscularis layer of gizzard or villus height, crypt depth, goblet cell numbers or epithelial thickness in the ileum. 6. Improved performance observed with post-pelleting inclusion of whole wheat was associated with increased size of the gizzard and improved AME. The gizzard development hypothesis, however, will not explain the improvements observed with pre-pelleting inclusion of whole wheat, suggesting the involvement of other factors.
Collapse
Affiliation(s)
- Y B Wu
- Institute of Food, Nutrition and Human Health, Massey University, Palmerston North, New Zealand
| | | | | | | | | |
Collapse
|
48
|
Thomas DG, Ravindran V, Thomas DV, Camden BJ, Cottam YH, Morel PCH, Cook CJ. Influence of stocking density on the performance, carcass characteristics and selected welfare indicators of broiler chickens. N Z Vet J 2004; 52:76-81. [PMID: 15768100 DOI: 10.1080/00480169.2004.36408] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
AIM To compare the effects of four stocking densities (5, 10, 15 or 20 birds per m2) on the performance, carcass characteristics and selected welfare indicators of broiler chickens. METHODS A total of 756 day-old male broiler chicks were assigned as six replicates of 13, 25, 38 and 50 birds per pen, to stocking densities of 2,000, 1,000, 667 and 500 cm2 floor space per bird, respectively. The birds were housed in floor pens in an environmentally controlled room. Normal commercial diets were fed ad libitum and fresh water was freely available throughout the 5-week study period. Liveweights of birds and feed intake were recorded at weekly intervals. Data on carcass parameters and welfare indicators (moisture, gait scores, feather scores, breast and hip lesions, and foot pad and hock burns) were obtained on Day 35. Adrenal glands were removed at slaughter, weighed and examined histologically to determine the total proportion of cortical and medullary tissues. RESULTS During the study, the birds at the lowest density grew faster (p<0.001-0.01) and consumed more (p<0.001- 0.01) feed than those at the other three stocking densities. The liveweight gains and feed intake of birds reared at densities of 10, 15 and 20 birds per m2 were similar (p=0.11-0.83 and p=0.17-0.57, respectively). Stocking density had no influence on the feed/weight gain, mortality or carcass characteristics. No breast or hip lesions were observed in carcasses from any of the groups. The weight and structure of the adrenal glands were similar across all groups although the staining of medullary tissue of birds was most intense in the highest stocking density group. As stocking density increased, so did moisture and gait score, hock and foot pad burn scores, and the feather score was adversely affected. CONCLUSIONS The data showed that the relationship between stocking density and productivity traits was not linear in nature, in accordance with other studies. Under the conditions of the current study, the performance, mortality and carcass characteristics of broilers grown at densities of 10, 15 and 20 birds per m2 were similar. There were some welfare implications at high population densities as indicated by adverse effects on litter quality, gait scores and the incidence of hock and foot pad burns.
Collapse
Affiliation(s)
- D G Thomas
- Institute of Food, Nutrition and Human Health, Massey University, Private Bag 11222, Palmerston North, New Zealand
| | | | | | | | | | | | | |
Collapse
|
49
|
Wu YB, Ravindran V, Thomas DG, Birtles MJ, Hendriks WH. Influence of phytase and xylanase, individually or in combination, on performance, apparent metabolisable energy, digestive tract measurements and gut morphology in broilers fed wheat-based diets containing adequate level of phosphorus. Br Poult Sci 2004; 45:76-84. [PMID: 15115204 DOI: 10.1080/00071660410001668897] [Citation(s) in RCA: 105] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
1. The aim of the present study was to examine the influence of microbial phytase and xylanase, individually or in combination, on performance, apparent metabolisable energy, digesta viscosity, digestive tract measurements and gut morphology in broilers fed on wheat-soy diets containing adequate phosphorus (P). The wheat-soy basal diet was formulated to contain 4.5 g/kg non-phytate P and the experimental diets were formulated by supplementing the basal diet with xylanase (1000 xylanase units/kg diet), phytase (500 phytase units/kg diet) or a combination of phytase and xylanase. 2. Supplemental phytase improved the weight gains and feed efficiency by 17.5 and 2.9%, respectively. Corresponding improvements due to the addition of xylanase were 16.5 and 4.9%, respectively. The combination of phytase and xylanase caused no further improvements in broiler performance. 3. Individual additions of xylanase or phytase resulted in numerical improvements in apparent metabolisable energy (AME), but the differences were not significant. The combination of the two enzymes significantly increased AME. Addition of xylanase and the combination of the two enzymes reduced the viscosity of digesta in all sections of the intestine. Phytase supplementation reduced digesta viscosity in the duodenum and ileum, but not in the jejunum. 4. Enzyme supplementation lowered the relative weight and length of the small intestine. Additions of xylanase and phytase reduced the relative weight of the small intestine by 15.5 and 11.4%, respectively, while the corresponding reductions in the relative length of the small intestine were 16.5 and 14.1%, respectively. The combination of phytase and xylanase had no further effects on the relative weight and length of the small intestine compared with the xylanase group. 5. The addition of phytase increased villus height in the duodenum and decreased the number of goblet cells in the jejunum compared with those on the unsupplemented basal diet. Xylanase supplementation tended to increase goblet cell numbers in the duodenum and decreased crypt depth in thejejunum. The combination of phytase and xylanase increased villus height in the ileum and crypt depth in thejejunum and ileum. 6. In summary, the present results showed that the addition of a microbial phytase, produced by solid state fermentation and containing significant activities of beta-glucanase and xylanase, was as effective as xylanase in improving the performance of broiler chickens fed on wheat-based diets containing adequate levels of P. Improved performance with enzyme supplementation was generally associated with reduced digesta viscosity, increased AME, and reduced relative weight and length of small intestine.
Collapse
Affiliation(s)
- Y B Wu
- Institute of Food, Nutrition and Human Health and Institute of Veterinary, Animal and Biomedical Sciences, Massey University, Palmerston North, New Zealand
| | | | | | | | | |
Collapse
|
50
|
Bayly PJ, Matthews JN, Dobson PM, Price ML, Thomas DG. In-hospital mortality from abdominal aortic surgery in Great Britain and Ireland: Vascular Anaesthesia Society audit. Br J Surg 2002; 88:687-92. [PMID: 11350442 DOI: 10.1046/j.0007-1323.2001.01778.x] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Abstract
Background
The mortality rate associated with elective aortic aneurysm repair is widely assumed to be in the region of 5 per cent. This figure does not take into consideration the effect of pre-existing risk factors. The Vascular Anaesthesia Society of Great Britain and Ireland conducted a large audit to estimate the in-hospital mortality rate associated with non-emergency infrarenal aortic surgery throughout the British Isles, and to determine the influence of risk factors on mortality rate.
Methods
This was a multicentre, prospective audit of 177 hospitals throughout the UK and Ireland. Data were collected by questionnaire to include all patients undergoing elective or urgent surgery for infrarenal abdominal aortic aneurysm or aortoiliac occlusive disease over 4 months.
Results
Nine hundred and thirty-three patients were recruited into the audit. The overall mortality rate was 7·3 per cent. Factors increasing the risk of death by up to fivefold included age over 74 years, urgent surgery, operation for occlusive disease, limited exercise capacity, a history of severe angina or cardiac failure, the presence of ventricular ectopics and abnormalities suggesting ischaemic heart disease on electrocardiography.
Conclusion
Although the in-hospital mortality rate was similar to previously published figures, the rate increased considerably when commonly encountered risk factors were present.
Collapse
Affiliation(s)
- P J Bayly
- Department of Anaesthetics, Freeman Hospital, Newcastle upon Tyne, UK.
| | | | | | | | | |
Collapse
|